Stryker (SYK) Delivers Q2 2026 Earnings Beat with +17.9% EPS Growth, but Shares Drop -9%
Key Takeaways
- Adjusted earnings per share (EPS) came in at $3.69, surpassing the consensus estimate of $3.49 by $0.20 and reflecting a 17.9% increase from $3.13 in the same quarter last year.
- Revenue reached $6.59 billion, edging past analyst expectations of $6.58 billion and representing year-over-year growth of 9.4%.
- Organic net sales growth was 9.0%, driven by strong unit volume across both the MedSurg and Neurotechnology segment and the Orthopaedics segment.
- Full-year 2026 guidance was narrowed: organic sales growth is now projected at 8.3% to 9.3%, while adjusted EPS is expected between $14.95 and $15.10.
- Despite the beats, shares fell approximately 9% in after-hours trading, suggesting investors were focused on the limited guidance upgrade and the second-half execution ramp.
- The quarter marked a meaningful recovery from the March 2026 cybersecurity incident that disrupted first-quarter operations and delayed revenue recognition.
Why This Quarter Matters
SYK’s second-quarter 2026 results arrived at a pivotal moment. The company entered this reporting cycle under heightened investor scrutiny following a March cyberattack that disrupted its Microsoft systems, delayed product shipments, and contributed to a significant first-quarter earnings miss. With Q1 adjusted EPS falling 12.75% short of consensus, the market was eager to see whether SYK could recapture momentum. The Q2 report was therefore viewed as a critical litmus test for the company’s operational resilience and its ability to recover deferred revenue. As one of the largest medical technology companies in the world, SYK’s performance also served as a broader read on procedural demand trends, hospital capital spending, and the pace of robotic surgery adoption across the medtech industry.
Breaking Down the Q2 Numbers
SYK reported second-quarter 2026 net sales of $6.59 billion, an increase of 9.4% compared to $6.02 billion in the prior-year period. Organic net sales — which exclude the impact of foreign currency and acquisitions — rose 9.0%, fueled entirely by higher unit volume. The MedSurg and Neurotechnology segment generated $3.63 billion in revenue, up 9.7% year over year, with organic growth of 9.2% led by a 13.4% surge in the Medical business, which includes patient handling and emergency care equipment. Orthopaedics delivered $2.96 billion in sales, up 9.1%, with organic growth of 8.6%. Trauma and extremities led the orthopaedic sub-segments at 11.9% growth, while knee implants rose 8.4% and hips grew 2.9%.
On the bottom line, reported net earnings were $1.28 billion, or $3.30 per diluted share, compared to $884 million, or $2.29 per share, a year ago. Adjusted EPS — which strips out one-time items — climbed 17.9% to $3.69, exceeding the FactSet consensus of $3.49. Adjusted gross margin expanded 60 basis points to 66.0%, and adjusted operating margin rose 170 basis points to 27.4%, helped by a net tariff benefit, favorable business mix, and cost discipline.
Management also narrowed full-year 2026 guidance. Organic net sales growth is now expected in the range of 8.3% to 9.3%, tightened from the prior 8.0% to 9.5%. Adjusted EPS guidance moved to $14.95 to $15.10, raising the lower end from the previous $14.90. The update signaled confidence but left limited room for upside relative to consensus, which stood at $14.97. When screening peers in the space, I also checked this using Tickeron’s AI Screener to see how SYK compares to others in the industry.
How the Market Reacted
SYK shares closed the regular trading session on July 30 at $348.37, down roughly 1.1% on the day. However, the stock dropped approximately 9% in after-hours trading, slipping to around $316, following the earnings release and conference call. The sharp selloff — despite beats on both the top and bottom lines — highlighted investor unease around the pace of recovery and the second-half outlook. While quarterly results demonstrated that operations had stabilized following the cyberattack, the narrowed full-year guidance was perceived as conservative rather than bullish, leaving minimal room for upward revisions. Additionally, with the stock trading near the higher end of its broader range heading into the report, some profit-taking may have amplified the post-earnings move. The decline underscores how, in the current market environment, beating quarterly estimates may not be enough to satisfy expectations when the forward path lacks a clear catalyst for acceleration.
What to Watch Going Forward
Looking ahead, investors will closely track several factors that could shape SYK’s performance through the remainder of fiscal 2026. The company enters the second half with regained momentum and an elevated order backlog, particularly in its capital equipment business — a segment expected to be a major growth driver in the coming quarters. Management emphasized that there were zero cancellations in the order book, a reassuring signal for demand durability.
One area of focus will be the ongoing recovery from the March cyberattack. While Q2 results showed substantial progress, the full catch-up of deferred revenues is expected to extend through the second half of the year. Any delays or setbacks in this recovery timeline could weigh on investor confidence. The trajectory of adjusted operating margins also warrants attention. The 170-basis-point improvement in Q2 benefited in part from a net tariff benefit; changes in trade policy or supply chain costs could alter that equation.
On the innovation front, the Mako SmartRobotics platform remains a key growth pillar. SYK reported its best-ever second quarter for Mako installations globally, with systems now deployed in 47 countries and over 2.5 million procedures completed worldwide. The recent launch of the Mako RPS platform for robotic knee surgery could broaden the addressable market. Additionally, procedural volume trends across orthopaedics and MedSurg will serve as a real-time gauge of underlying demand as hospital staffing and capacity constraints continue to normalize. With narrowed guidance and a demanding second-half setup, execution will be paramount.
Enhancing My Research Process
In my view, tools like Tickeron’s AI Screener help cut through the noise during earnings season by quickly highlighting comparable names and technical setups. I ran a quick scan on the medical technology sector to cross-check volume trends and margin patterns across peers, which added useful context to the SYK results without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SYK in +2.69% Uptrend, growing for three consecutive days on August 11, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SYK advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on SYK as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on July 27, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
SYK moved above its 50-day moving average on July 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The Aroon Indicator entered an Uptrend today. In of 251 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SYK broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.552) is normal, around the industry mean (10.811). P/E Ratio (35.980) is within average values for comparable stocks, (72.873). Projected Growth (PEG Ratio) (1.636) is also within normal values, averaging (3.982). Dividend Yield (0.010) settles around the average of (0.016) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (37.357).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products
Industry MedicalNursingServices
Advertisement